Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-07-05
2011-07-05
Juedes, Amy E (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
07972797
ABSTRACT:
The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention describes a gene known in the art, alternatively, as ST2, T1 and Fit-1, and referred to herein as the 103 gene. The 103 gene is disclosed herein to be differentially expressed in TH2 cells and not in TH1 cells. Further, the 103 gene product is demonstrated herein to be an important modulator of TH2 and TH2-like immune response both in vitro and in vivo. Thus, the 103 gene, its gene products and antibodies that specifically bind thereto can be used diagnostically or as targets for therapeutic intervention in the treatment of a variety of immune disorders.In this regard, the invention provides methods for the identification and therapeutic use of compounds for treatments of immune disorders, especially TH cell subpopulation-related disorders and including TH2 and TH2-like disorders (i.e., disorders associated with a TH2 or TH2-like mediated immune response) such as atopic conditions (e.g., allergy and asthma). Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders and for monitoring the efficacy of compounds used in clinical trials.
REFERENCES:
patent: 4281061 (1981-07-01), Zuk et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5262311 (1993-11-01), Pardee et al.
patent: 5591719 (1997-01-01), Furcht et al.
patent: 5721351 (1998-02-01), Levinson
patent: 5840691 (1998-11-01), Furcht et al.
patent: 2005/0119209 (2005-06-01), Levinson et al.
patent: 239400 (1994-08-01), None
patent: 6-178687 (1994-06-01), None
patent: WO 97/42224 (1997-11-01), None
patent: WO 99/15663 (1999-04-01), None
patent: WO 9934217 (1999-07-01), None
Altschul et al., 1997, “Gapped Blast and PSI-Blast: a new generation of protein database search programs”, Nucl Acids Res 25:3389-3402.
Altschul et al., 1990, “Basic Local Alignment Search Tool”, J. Mol. Biol. 215:403-410.
Anderson and Coyle, 1994, “TH2 and ‘TH2-like’ cells in allergy and asthma: pharmacological perspectives”, Trends Pharmacol. Sci. 15:324-332.
Aruffo et al., 1990, “CD44 is the principal cell surface receptor for hyaluronate”, Cell 61:1303-1313.
Bergers et al., 1994, “Alternative promoter usage of the Fos-responsive geneFit-1generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor”, EMBO J. 13:1176-1188 .
Chen et al., 1993, “RAG-2-deficient blastocyst complementation: an assay of gene function in lymphocyte development”, Proc. Natl. Acad. Sci. USA 90:4528-4532.
Clerici et al., 1993, “Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro”, Science 262:1721-1724.
Clerici et al., 1993, “Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals”, J. Clin. Invest. 91:759-765.
Cohn et al., 1997, “Induction of airway mucus production by T helper 2 (Th2) cells: a critical role for interleukin 4 in cell recruitment but not mucus production”, J. Exp. Med. 186:1737-1747.
Del Prete et al., 1991 , “Purified protein derivative ofMycobacterium tuberculosisand excretory-secretory antigen(s) ofToxocara canisexpand in vitro human T cells with stable and opposite (Type 1 T helper or Type 2 T helper) profile of cytokine production”, J. Clin. Invest. 88:346-350.
Fägerstam et al., 1992, “Biospecific interaction analysis using surface plasmon resonance detection applied to kinetic, binding site and concentration analysis”, J. Chromatog. 597:397-410.
Firestein et al., 1989, “A new murine CD4+T cell subset with an unrestricted cytokine profile”, J. lmmunol. 143:518-525.
Frangogiannis et al., 1998, “Resident cardiac mast cells degranulate and release preformed TNF-α initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion”, Circulation 98:699-710.
Gächter et al., 1996, “Transcription of the interleukin-1 receptor-related T1 gene is initiated at different promoters in mast cells and fibroblasts”, J. Biol. Chem. 271:124-129.
Gavett et al., 1994, “Depletion of murine CD4+T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia”, Am. J. Respir Cell Mol. Biol. 10:587-593.
George et al., 1994, “Embryonic expression and cloning of the murine GATA-3 gene”, Development 120:2673-2686.
Gonazlo et al., 1996, “Mouse eotaxin expression parallels eosinophil accumulation during lung allergic inflammation but it is not restricted to a Th2-type response”, Immunity 4:1-14.
Gu et al., 1994, “Deletion of a DNA polymerase β gene segment in T cells using cell type-specific gene targeting”, Science 265:103-106.
Hamelmann et al., 1997, “Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography”, Am. J. Respir. Crit. Care Med. 156:766-775.
Holgate, 1997, “The cellular and mediator basis of asthma in relation to natural history”, Lancet 350 (Suppl. 2):5-9.
Kanagawa et al., 1993, “Resistance of mice deficient in IL-4 to retrovirus-induced immunodeficiency syndrome (MAIDS)”, Science 262:240-242.
Kaneshima et al., 1994, “Human hematolymphoid cells in SCID mice”, Curr. Opin. Immunol. 6:327-333.
Karlin and Altschul, 1993, “Applications and statistics for multiple high-scoring segments in molecular sequences”, Proc. Natl. Acad. Sci. USA 90:5873-5877.
Karlin and Altschul, 1990, “Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes”, Proc Natl Acad Sci USA 87:2264-2268.
Klemenz et al., 1989, “Serum- and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen”, Proc. Natl. Acad. Sci. USA 86:5708-5712.
Ko and Engel, 1993, “DNA binding specificities of the GATA transcription factor family”, Mol. Cell. Biol. 13:4011-4022.
Kumar et al., 1997, “Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli”, Biochem. Biophys. Res. Comm. 235:474-478.
Liew, 1994, “Induction and regulation of CD4+T cell subsets”, CIBA Foundation Symposium 87:170-178.
Löhning et al., 1998, “T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function”, Proc. Natl. Acad. Sci. USA 95:6930-6935.
Lukacs et al., 1994, “Interleukin-4-dependent pulmonary eosinophil infiltration in a murine model of asthma”, Am. J. Respir. Cell Mol. Biol. 10:526-532.
Maggi et al., 1994, “Th2-like CD8+T cells showing B cell helper function and reduced cytolytic activity in human immunodeficiency virus type 1 infection”, J. Exp. Med. 180:489-495.
Maggi et al., 1994, “Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 to TH0 cells”, Science 265:244-248.
Makino et al., 1990, “H-2-associated and background genes influence the development of a murine retrovirus-induced immunodeficiency syndrome”, J. Immunol. 144:4347-4355.
Manetti et at., 1994, “CD30 expression by CD8+T cells producing type 2 helper cytokines. Evidence for large numbers of CD8+CD30+T cell clones in human immunodeficiency virus infection”, J. Exp. Med. 180:2407-2411.
McMahan et al., 1991, “A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types”, EMBO J. 10:2821-2832.
Metzler an
Kingsbury Gillian A.
Leiby Kevin R.
Juedes Amy E
Millennium Pharmaceuticals Inc.
LandOfFree
Compositions and methods for the diagnosis and treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the diagnosis and treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the diagnosis and treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2653229